{Reference Type}: Journal Article
{Title}: Meibomian Gland Shortening Is Associated With Altered Meibum Composition.
{Author}: Iqbal F;Stapleton F;Masoudi S;Papas EB;Tan J;
{Journal}: Invest Ophthalmol Vis Sci
{Volume}: 65
{Issue}: 8
{Year}: 2024 Jul 1
{Factor}: 4.925
{DOI}: 10.1167/iovs.65.8.49
{Abstract}: <B>UNASSIGNED: </B>The purpose of this study was to investigate differences in the composition of meibum extracted from human meibomian glands displaying different morphological characteristics.<BR><B>UNASSIGNED: </B>Adult participants with evidence of meibomian gland shortening were enrolled. Glands were observed using infrared meibography, and meibum was collected from one short and one long gland from the lower eyelid of the same eye. Total protein concentration was evaluated using the detergent compatible (DC) protein assay and lipid analysis was performed using liquid chromatography mass spectrometry.<BR><B>UNASSIGNED: </B>Fifteen participants (8 women and 7 men) completed the study (mean age = 34.7 ± 7.7 years). The average volume of meibum collected from the short and long glands was 0.02 ± 0.01 and 0.05 ± 0.03 µL, respectively (P = 0.01). Average protein concentration in the short glands was significantly higher compared to the long glands (0.10 ± 0.03 vs. 0.08 ± 0.02 mg/mL, P = 0.01). Among the non-polar lipids, the mole percent of cholesterol esters (CEs; P = 0.02), triacylglycerols (TAGs; P = 0.04), and ceramide (Cer; P = 0.03) was significantly lower in short glands compared with long glands. Among the polar lipids, the mole percent of (O-acyl)-ω-hydroxy fatty acid (OAHFA; P = 0.01) was significantly lower in short glands, whereas phosphatidylcholine (PC; P = 0.02) and sphingomyelin (SM; P = 0.01) were significantly higher in short glands than long glands.<BR><B>UNASSIGNED: </B>Meibum composition differed between short and long glands. The lower mole percent of CE, TAG, OAHFA, and Cer and a higher mole percent of PC and SM among short glands may indicate disease activity. This information may clarify the natural history of meibomian gland dysfunction and future targets for therapy.